Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

OABI

OmniAb Inc

Jul 26 • 04:00PM ET

4.84

Dollar change +0.04
Percentage change 0.83	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWN SCHA VTWO DFAS VHT DFAC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.63	Insider Own	19.56%	Shs Outstand	116.86M	Perf Week	3.86%
Market Cap	566.91M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	1.95%	Shs Float	94.22M	Perf Month	24.74%
Income	-63.48M	PEG	-	EPS next Q	-0.17	Inst Own	59.00%	Short Float	8.84%	Perf Quarter	9.26%
Sales	21.05M	P/S	26.93	EPS this Y	-24.02%	Inst Trans	0.72%	Short Ratio	12.48	Perf Half Y	-20.26%
Book/sh	2.57	P/B	1.89	EPS next Y	34.95%	ROA	-16.58%	Short Interest	8.33M	Perf Year	-9.36%
Cash/sh	0.59	P/C	8.21	EPS next 5Y	-	ROE	-19.77%	52W Range	3.56 - 6.72	Perf YTD	-21.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-19.66%	52W High	-27.92%	Beta	-0.15
Dividend TTM	-	Quick Ratio	4.38	Sales past 5Y	13.92%	Gross Margin	6.93%	52W Low	35.96%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	4.38	EPS Y/Y TTM	-384.71%	Oper. Margin	-395.91%	RSI (14)	66.55	Volatility	3.79% 4.57%
Employees	106	Debt/Eq	0.08	Sales Y/Y TTM	-59.73%	Profit Margin	-301.63%	Recom	1.00	Target Price	9.88
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-206.02%	Payout	-	Rel Volume	0.61	Prev Close	4.80
Sales Surprise	-35.24%	EPS Surprise	-17.79%	Sales Q/Q	-77.53%	Earnings	Aug 08 AMC	Avg Volume	667.52K	Price	4.84
SMA20	12.79%	SMA50	12.31%	SMA200	-3.32%	Trades		Volume	405,899	Change	0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
08:56PM	Loading…
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
04:30PM	Loading…
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
04:05PM	Loading…
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Avista Capital Managing Member	10% Owner	Jun 29 '24	Option Exercise	3.35	66,668	223,338	15,992,372	Jul 02 05:00 PM
FOEHR MATTHEW W	President and CEO	Jun 27 '24	Option Exercise	3.73	59,659	222,416	3,599,166	Jun 27 04:55 PM
FOEHR MATTHEW W	President and CEO	May 24 '24	Buy	4.42	240,000	1,059,840	3,536,665	May 28 05:55 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 08 '24	Sale	5.27	6,954	36,648	176,697	Apr 09 06:38 PM
Berkman Charles S	Chief Legal Officer	Apr 08 '24	Sale	5.27	6,954	36,648	292,617	Apr 09 06:37 PM
GUSTAFSON KURT A	Executive VP, Finance & CFO	Apr 01 '24	Sale	5.46	11,849	64,696	170,110	Apr 02 06:30 PM
FOEHR MATTHEW W	President and CEO	Mar 27 '24	Option Exercise	3.72	243,613	907,023	3,152,416	Mar 29 04:52 PM
FOEHR MATTHEW W	President and CEO	Mar 22 '24	Buy	5.19	225,000	1,167,750	2,908,803	Mar 25 07:07 AM
FOEHR MATTHEW W	Chief Executive Officer	Dec 12 '23	Buy	5.05	200,000	1,010,000	2,645,442	Dec 13 03:25 PM
FOEHR MATTHEW W	President and CEO	Nov 10 '23	Buy	4.27	95,000	405,517	2,427,919	Nov 13 08:00 AM
FOEHR MATTHEW W	President and CEO	Aug 14 '23	Buy	5.48	45,000	246,600	2,332,919	Aug 15 04:56 PM

Open in Screener

LGND

Ligand Pharmaceuticals, Inc.

Jul 26 • 04:00PM ET

107.14

Dollar change +1.13
Percentage change 1.07	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

LGND Ligand Pharmaceuticals, Inc. daily Stock Chart

Held by: IJR IWM VTI VB VBR VXF IJS IWN SPSM IBB

Index	RUT	P/E	20.14	EPS (ttm)	5.32	Insider Own	2.54%	Shs Outstand	17.56M	Perf Week	7.40%
Market Cap	1.92B	Forward P/E	17.43	EPS next Y	6.15	Insider Trans	-8.77%	Shs Float	17.51M	Perf Month	37.68%
Income	96.34M	PEG	1.01	EPS next Q	0.98	Inst Own	92.74%	Short Float	6.28%	Perf Quarter	52.25%
Sales	118.31M	P/S	16.26	EPS this Y	-20.51%	Inst Trans	-0.32%	Short Ratio	7.94	Perf Half Y	42.30%
Book/sh	45.00	P/B	2.38	EPS next Y	26.98%	ROA	11.17%	Short Interest	1.10M	Perf Year	58.21%
Cash/sh	17.29	P/C	6.20	EPS next 5Y	20.00%	ROE	13.26%	52W Range	49.24 - 108.91	Perf YTD	50.01%
Dividend Est.	-	P/FCF	59.83	EPS past 5Y	-13.18%	ROI	11.87%	52W High	-1.63%	Beta	1.00
Dividend TTM	-	Quick Ratio	19.51	Sales past 5Y	-3.89%	Gross Margin	64.12%	52W Low	117.59%	ATR (14)	3.77
Dividend Ex-Date	Jul 02, 2010	Current Ratio	20.70	EPS Y/Y TTM	290.26%	Oper. Margin	-1.18%	RSI (14)	77.67	Volatility	4.23% 4.30%
Employees	58	Debt/Eq	0.01	Sales Y/Y TTM	-45.70%	Profit Margin	81.43%	Recom	1.20	Target Price	117.80
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	103.66%	Payout	0.00%	Rel Volume	0.64	Prev Close	106.01
Sales Surprise	10.94%	EPS Surprise	43.88%	Sales Q/Q	-29.56%	Earnings	Aug 06 AMC	Avg Volume	138.51K	Price	107.14
SMA20	13.75%	SMA50	22.52%	SMA200	46.24%	Trades		Volume	88,710	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169
Sep-05-17	Resumed	H.C. Wainwright	Buy	$150
Oct-05-16	Reiterated	H.C. Wainwright	Buy	$146 → $160
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell	$104 → $110

Show Previous Ratings

Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
08:00AM	Loading…
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
01:22PM	Loading…
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
11:30AM	Loading…
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations (GlobeNewswire)
Dec-11-23 09:00AM	Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology (GlobeNewswire)
Dec-06-23 04:02PM	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Business Wire)
Dec-01-23 08:20AM	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications (GlobeNewswire)
Nov-28-23 09:01AM	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-23 04:47PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:01PM	Ligand Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 09:00AM	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial (GlobeNewswire)
Nov-01-23 08:00AM	Ligand Acquires Royalty on Sanofis TZIELD for $20 Million (Business Wire)
Oct-25-23 04:01PM	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Business Wire)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire)
Oct-09-23 06:15PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-03-23 06:00PM	Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know (Zacks)
Oct-02-23 09:00AM	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms (GlobeNewswire)
Sep-27-23 09:00AM	Ligand Acquires Assets of Novan, Inc. for $12.2 Million (Business Wire)
Sep-26-23 05:05PM	Ligand Appoints Martine Zimmermann to its Board of Directors (Business Wire)
Sep-22-23 09:00AM	Ligands Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (Business Wire)
Sep-21-23 09:20AM	Ligands Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control (Business Wire)
Sep-18-23 05:17PM	Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio (Business Wire)
Sep-01-23 10:02PM	Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 04:01PM	Ligand Reports Second Quarter 2023 Financial Results (Business Wire) +5.35%
Jul-27-23 01:30PM	Ligands Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials (Business Wire)
Jul-25-23 04:30PM	Ligand To Report Second Quarter 2023 Financial Results On August 8 (Business Wire)
Jul-17-23 08:59AM	Ligand Offers $15 Million to Acquire Assets of Novan, Inc. (Business Wire)
08:45AM	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection (GlobeNewswire)
Jun-29-23 09:00AM	Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting (GlobeNewswire)
Jun-21-23 08:00PM	LGND: Lowering target price to $81.00 (Argus Research)
Jun-09-23 09:40AM	Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-06-23 11:40AM	LGND or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
11:10AM	UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health (Zacks)
Jun-05-23 11:49AM	Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat (Zacks) -5.72%
09:01AM	Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer (GlobeNewswire)
Jun-02-23 12:39PM	FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer (Zacks) +5.77%
12:35PM	Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study (Zacks)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-30-23 07:01PM	3 Stocks That Smart Investors Should Be Flocking to Now (InvestorPlace)
May-25-23 05:00PM	Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023 (GlobeNewswire)
May-24-23 09:55AM	Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet (Zacks)
09:40AM	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? (Zacks)
May-17-23 01:59PM	Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study (Zacks)
08:07AM	Zacks.com featured highlights include J.B. Hunt Transport Services, Archer-Daniels-Midland, NVIDIA, Tractor Supply and AmerisourceBergen (Zacks)
May-16-23 09:56AM	Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far (Zacks)
07:30AM	Ligands Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) (Business Wire)
07:00AM	Load Up on These 5 Exceptional Relative Price Strength Stocks (Zacks)
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 12:32PM	Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings (Zacks)
09:55AM	Wall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to Trade (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Espinoza Octavio	Chief Financial Officer	May 17 '24	Option Exercise	55.71	6,917	385,346	28,535	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 17 '24	Sale	86.66	5,156	446,844	23,379	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 16 '24	Sale	86.00	2,264	194,712	21,618	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 15 '24	Sale	86.01	5,873	505,148	23,882	May 17 07:59 PM
Korenberg Matthew E	President & Chief Operating	May 14 '24	Sale	85.10	14,158	1,204,912	86,263	May 15 07:34 PM
Korenberg Matthew E	President & Chief Operating	May 13 '24	Sale	84.54	3,440	290,828	100,421	May 15 07:34 PM
Reardon Andrew	Chief Legal Officer &	May 09 '24	Option Exercise	52.27	10,000	522,700	32,205	May 13 05:32 PM
Reardon Andrew	Chief Legal Officer &	May 09 '24	Sale	83.04	10,000	830,449	22,205	May 13 05:32 PM
Gray Nancy Ryan	Director	May 09 '24	Sale	83.20	934	77,713	5,633	May 17 08:00 PM
Aryeh Jason	Director	Apr 30 '24	Option Exercise	52.30	2,406	125,834	76,828	May 02 06:07 PM
KOZARICH JOHN W	Director	Apr 24 '24	Option Exercise	39.35	2,893	113,840	42,523	Apr 26 06:35 PM
Davis Todd C	Chief Executive Officer	Mar 25 '24	Option Exercise	57.39	16,015	919,147	120,160	Mar 27 05:47 PM
Aryeh Jason	Director	Mar 05 '24	Option Exercise	39.35	2,893	113,840	74,422	Mar 06 05:28 PM
Sabba Stephen L	Director	Mar 05 '24	Option Exercise	0.00	2,893	0	30,819	Mar 07 01:27 PM
Sabba Stephen L	Director	Mar 05 '24	Sale	74.30	1,893	140,650	28,926	Mar 07 01:27 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Option Exercise	56.62	1,264	71,564	29,895	Feb 29 06:50 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Sale	88.46	140	12,384	29,755	Feb 29 06:50 PM
Davis Todd C	CHIEF EXECUTIVE OFFICER	Sep 22 '23	Buy	59.38	4,000	237,529	73,090	Sep 25 04:44 PM

Open in Screener

TECH

Bio-Techne Corp

Jul 26 • 04:00PM ET

80.60

Dollar change +1.93
Percentage change 2.45	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VB VBK SPY IVV RSP XLV IBB IWR

Index	S&P 500	P/E	64.06	EPS (ttm)	1.26	Insider Own	1.03%	Shs Outstand	157.64M	Perf Week	6.81%
Market Cap	12.70B	Forward P/E	39.99	EPS next Y	2.02	Insider Trans	-0.88%	Shs Float	155.96M	Perf Month	11.79%
Income	202.97M	PEG	11.52	EPS next Q	0.49	Inst Own	101.88%	Short Float	2.42%	Perf Quarter	28.63%
Sales	1.15B	P/S	11.00	EPS this Y	-10.52%	Inst Trans	1.97%	Short Ratio	3.51	Perf Half Y	13.33%
Book/sh	12.79	P/B	6.30	EPS next Y	13.19%	ROA	7.63%	Short Interest	3.77M	Perf Year	-5.15%
Cash/sh	0.92	P/C	87.41	EPS next 5Y	5.56%	ROE	10.40%	52W Range	51.79 - 85.95	Perf YTD	4.46%
Dividend Est.	0.25 (0.32%)	P/FCF	50.57	EPS past 5Y	16.30%	ROI	8.13%	52W High	-6.22%	Beta	1.27
Dividend TTM	0.32 (0.40%)	Quick Ratio	2.88	Sales past 5Y	12.76%	Gross Margin	66.96%	52W Low	55.63%	ATR (14)	2.25
Dividend Ex-Date	May 10, 2024	Current Ratio	4.08	EPS Y/Y TTM	-25.45%	Oper. Margin	21.92%	RSI (14)	64.44	Volatility	3.21% 2.92%
Employees	3050	Debt/Eq	0.25	Sales Y/Y TTM	2.73%	Profit Margin	17.58%	Recom	1.81	Target Price	84.11
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	-29.65%	Payout	18.16%	Rel Volume	0.90	Prev Close	78.67
Sales Surprise	3.86%	EPS Surprise	6.01%	Sales Q/Q	3.16%	Earnings	Aug 07 BMO	Avg Volume	1.07M	Price	80.60
SMA20	7.82%	SMA50	4.86%	SMA200	13.79%	Trades		Volume	969,063	Change	2.45%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-24	Downgrade	Citigroup	Buy → Neutral	$85
Feb-08-24	Initiated	Scotiabank	Sector Outperform	$80
Feb-02-24	Downgrade	Stifel	Buy → Hold	$65
Dec-07-23	Initiated	UBS	Buy	$80
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$90
Dec-14-22	Initiated	Deutsche Bank	Buy	$100
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$81.25 → $100
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform	$89
Aug-25-22	Initiated	Credit Suisse	Outperform	$465
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight	$370
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$600
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight	$380 → $425
Feb-23-21	Upgrade	Stifel	Hold → Buy	$435
Jan-25-21	Reiterated	The Benchmark Company	Buy	$320 → $410
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$340
Sep-30-20	Initiated	Atlantic Equities	Overweight	$365
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold	$245 → $260
May-14-20	Initiated	The Benchmark Company	Buy	$290

Show Previous Ratings

Jul-15-24 07:00AM	BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS (PR Newswire)
Jul-12-24 06:58PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Jul-09-24 06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-02-24 07:06PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
May-31-24 07:00AM	BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES (PR Newswire)
07:00AM	Loading…
May-30-24 07:00AM	BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex SYSTEM AT THE ANNUAL ASMS CONFERENCE (PR Newswire)
May-29-24 07:00AM	ScaleReady Announces $20 Million G-Rex Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing (PR Newswire)
May-23-24 10:26AM	Multiple Headwinds Dragged Bio-Techne Corp. (TECH) in Q1 (Insider Monkey)
07:00AM	BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE (PR Newswire)
May-22-24 07:00AM	BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY (PR Newswire)
May-20-24 01:34PM	7 Biotech Stocks That Could Breathe New Life Into Your Portfolio (InvestorPlace)
May-14-24 04:49AM	Bio-Techne Corporation (TECH) Declined on Weak Q4 Results (Insider Monkey)
May-08-24 07:00AM	BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024 (PR Newswire)
May-07-24 07:00AM	BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) (PR Newswire)
May-06-24 05:57AM	Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating (MT Newswires)
11:40AM	Loading…
May-02-24 11:40AM	Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript (Insider Monkey)
11:31AM	UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating (MT Newswires)
10:49AM	Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85 (MT Newswires)
10:34AM	Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80 (MT Newswires)
08:17AM	RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept (MT Newswires)
08:00AM	Baird Adjusts Bio-Techne Price Target to $81 From $73 (MT Newswires)
03:11AM	Bio-Techne Corp (TECH) (Q3 2024) Earnings Call Transcript Highlights: Navigating Market ... (GuruFocus.com)
May-01-24 04:54PM	S&P 500 Gains and Losses Today: CVS Falls as Health Care Costs Pressure Profits (Investopedia) +16.22%
02:05PM	Top Midday Gainers (MT Newswires)
01:52PM	Bio-Techne Is the Best Performing Stock in the S&P 500 Wednesday. Heres Why. (Barrons.com)
12:08PM	Update: Bio-Techne Shares Jump After Fiscal Q3 Beat (MT Newswires)
11:10AM	Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82 (MT Newswires)
09:30AM	Techne (TECH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:36AM	Bio-Techne's Fiscal Q3 Adjusted Earnings Fall, Net Sales Rise (MT Newswires)
07:51AM	Bio-Techne Corp (TECH) Q3 Fiscal 2024 Earnings: Mixed Results Amid Market Challenges (GuruFocus.com)
07:40AM	Loading…
07:40AM	Techne (TECH) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:29AM	Bio-Techne beats third-quarter estimates on improving demand for biotech products (Reuters)
06:30AM	BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
Apr-30-24 07:00AM	BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS (PR Newswire)
Apr-29-24 10:38AM	Bio-Techne to Enter Product Distribution Deal With Thermo Fisher Scientific (MT Newswires)
09:39AM	RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79 (MT Newswires)
07:00AM	BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC (PR Newswire)
Apr-26-24 07:00AM	BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY (PR Newswire)
Apr-24-24 10:01AM	Analysts Estimate Techne (TECH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-23-24 07:00AM	BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS (PR Newswire)
Apr-10-24 07:00AM	BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS (PR Newswire)
Apr-08-24 07:00AM	BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY (PR Newswire)
Apr-03-24 07:00AM	BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE (PR Newswire)
Apr-01-24 07:00AM	BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS (PR Newswire)
Mar-28-24 09:00AM	BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES (PR Newswire)
08:39AM	3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-22-24 07:00AM	BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA (PR Newswire)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-12-24 07:00AM	BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM (PR Newswire)
Mar-11-24 07:00PM	Director Roeland Nusse Sells 10,400 Shares of Bio-Techne Corp (TECH) (GuruFocus.com)
Mar-06-24 07:00AM	BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
Feb-23-24 06:15AM	What Makes Bio-Techne Corporation (TECH) an Investment Bet? (Insider Monkey)
Feb-13-24 08:00AM	The 3 Best Biotech Stocks to Buy in February 2024 (InvestorPlace)
Feb-02-24 10:47AM	Bio-Techne Corporation (NASDAQ:TECH) Q2 2024 Earnings Call Transcript (Insider Monkey)
04:45AM	Q2 2024 Bio-Techne Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-01-24 12:57PM	Bio-Techne Corp (TECH) Reports Mixed Q2 Fiscal 2024 Results Amid Industry Headwinds (GuruFocus.com)
07:51AM	Bio-Techne misses quarterly estimates on persistently weak demand in China (Reuters)
07:07AM	Bio-Techne Q2 Results Miss Estimates; Declares Dividend (RTT News)
06:30AM	BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
Jan-29-24 07:00AM	BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS (PR Newswire)
Jan-25-24 07:00AM	LUNAPHORE AND ACD REVOLUTIONIZE SPATIAL BIOLOGY RESEARCH WITH THE LAUNCH OF THE FIRST FULLY AUTOMATED, SAME-SECTION, HYPERPLEX MULTIOMICS APPLICATION (PR Newswire)
Jan-24-24 07:00AM	SCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex SYSTEM (PR Newswire)
Jan-21-24 01:16PM	3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-16-24 07:00AM	BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS (PR Newswire)
Jan-05-24 07:00AM	BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT (PR Newswire)
Jan-04-24 07:00AM	BIO-TECHNE TO SHOWCASE CELL AND GENE THERAPY MANUFACTURING TOOLS AT PHACILITATE ADVANCED THERAPIES WEEK 2024 (PR Newswire)
Dec-21-23 07:00AM	BIO-TECHNE TO PRESENT AT THE 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (PR Newswire)
Dec-20-23 07:00AM	BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY (PR Newswire)
Dec-14-23 07:00AM	LUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLS (PR Newswire)
Dec-01-23 01:32AM	Should You Hold Bio-Techne Corporation (TECH) For the Long Term? (Insider Monkey)
Nov-27-23 07:00AM	BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE (PR Newswire)
Nov-13-23 07:00AM	BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES (PR Newswire)
Nov-02-23 07:00AM	ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE (PR Newswire)
Nov-01-23 10:44AM	Bio-Techne Corporation (NASDAQ:TECH) Q1 2024 Earnings Call Transcript (Insider Monkey)
Oct-31-23 07:53AM	Bio-Techne Corp (TECH) Reports 2% Organic Revenue Growth in Q1 FY2024 (GuruFocus.com)
07:27AM	Bio-Techne's quarterly profit misses estimates as biotech funding woes persist (Reuters)
06:30AM	BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
Oct-25-23 03:42PM	3 AI Stock-Split Stocks to Buy Now (InvestorPlace)
09:00AM	LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING (PR Newswire)
Oct-22-23 10:30AM	Bearish Bets: 3 Stocks You Definitely Should Think About Shorting This Week (TheStreet.com)
Oct-20-23 05:01AM	Various Headwinds Pressured Bio-Techne Corporation (TECH) Shares in Q3 (Insider Monkey)
Oct-19-23 07:00AM	BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER (PR Newswire)
Oct-16-23 07:00AM	BIO-TECHNE ACHIEVES ISO 13485 CERTIFICATION FOR ITS WALLINGFORD, CT MANUFACTURING FACILITY (PR Newswire)
Oct-10-23 07:00AM	BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 31, 2023, TO ANNOUNCE FIRST QUARTER FISCAL 2024 FINANCIAL RESULTS (PR Newswire)
Oct-03-23 09:45AM	3 Healthcare Stocks to Keep an Eye On (Motley Fool)
Sep-28-23 06:00AM	DR. JORDAN LASER AWARDED AMP MERITORIOUS SERVICE AWARD (PR Newswire)
Sep-27-23 07:00AM	SCIENTISTS AT CE PHARM CONFERENCE DESCRIBE HOW Maurice AND MauriceFlex SYSTEMS TRANSFORM THEIR PROTEIN ANALYSIS (PR Newswire)
Sep-26-23 07:00AM	BIO-TECHNE INTEGRATES ITS MAURICE SYSTEM WITH THE THERMO SCIENTIFIC CHROMELEON CHROMATOGRAPHY DATA SYSTEM (PR Newswire)
Sep-25-23 07:00AM	BIO-TECHNE ISSUES 2023 CORPORATE SUSTAINABILITY REPORT (PR Newswire)
Sep-23-23 09:00AM	3 Healthcare Stocks That Should Be on Every Investors Radar This Fall (InvestorPlace)
Sep-19-23 02:00AM	Cizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western Platform (PR Newswire)
Sep-18-23 07:32PM	Unveiling Bio-Techne (TECH)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
10:14AM	Federal Reserve Likely to Maintain Rates Amid Mixed Economic Indicators (Investing.com)
Sep-08-23 11:35AM	Unveiling Bio-Techne (TECH)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-06-23 12:04PM	Unveiling the Investment Potential of Bio-Techne Corp (TECH): A Comprehensive Analysis of ... (GuruFocus.com)
Aug-28-23 07:32PM	Unveiling Bio-Techne (TECH)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hippel James	CFO	Jul 23 '24	Option Exercise	31.26	35,000	1,094,100	107,284	Jul 25 04:31 PM
HIGGINS JOHN L	Director	Jul 08 '24	Option Exercise	22.95	6,000	137,700	42,608	Jul 10 04:35 PM
HIGGINS JOHN L	Director	May 14 '24	Option Exercise	22.95	4,000	91,800	40,608	May 16 04:17 PM
HIGGINS JOHN L	Director	May 14 '24	Sale	83.84	4,000	335,377	36,608	May 16 04:17 PM
Nusse Roeland	Director	Mar 07 '24	Sale	76.98	10,400	800,627	43,097	Mar 11 04:04 PM
Hippel James	CFO	Dec 19 '23	Option Exercise	31.26	47,289	1,478,254	104,850	Dec 21 04:06 PM
Nusse Roeland	Director	Aug 30 '23	Option Exercise	22.40	32,000	716,800	60,811	Sep 01 04:06 PM
Nusse Roeland	Director	Aug 30 '23	Sale	80.32	8,939	717,959	51,872	Sep 01 04:06 PM
Kelderman Kim	Pres. Diagnostics & Genom	Aug 24 '23	Option Exercise	47.60	2,100	99,960	21,225	Aug 28 04:19 PM
Kummeth Charles R.	Chief Executive Officer	Aug 15 '23	Option Exercise	0.00	17,632	0	1,286,944	Aug 17 04:14 PM
Kummeth Charles R.	Chief Executive Officer	Aug 05 '23	Option Exercise	0.00	51,516	0	1,310,282	Aug 08 05:31 PM
Hippel James	CFO	Aug 05 '23	Option Exercise	0.00	12,876	0	63,896	Aug 08 05:29 PM
Kelderman Kim	Pres. Diagnostics & Genom	Aug 05 '23	Option Exercise	0.00	8,060	0	23,264	Aug 08 05:28 PM

OABI

OmniAb Inc

LGND

Ligand Pharmaceuticals, Inc.

TECH

Bio-Techne Corp

Upgrade your FINVIZ experience